Drug Profile
Research programme: pneumococcal polysaccharide vaccine 24-valent - Sinovac Biotech
Alternative Names: 24-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; Pneumococcal 24-valent vaccine - Sinovac Biotech; Pneumococcal polysaccharides vaccine - Sinovac Biotech; PPV - Sinovac BiotechLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sinovac Biotech
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections in China (Parenteral)
- 21 May 2014 Sinovac Biotech plans a phase I trial for Pneumococcal infections in China
- 01 May 2014 China FDA approves Clinical Trial Application for 24-valent Pneumococcal polysaccharide vaccine candidates